|Slideshows|November 5, 2018

Treat-to-Target in RA Hits the Bull’s-eye

Recent findings allay concerns about increased costs and rates of adverse events related to TTT strategies.

Reference1. Solomon DH, Yu Z, Katz JN, et al. Adverse events and resource use before and after treat to target in rheumatoid arthritis: a post-hoc analysis of a randomized controlled trial. Arthritis Care Res. 2018 Sep 17. doi: 10.1002/acr.23755. [Epub ahead of print]